• Home /
  • Research Grade Ulocuplumab (BMS-936564 / MDX-1338)

Research Grade Ulocuplumab (BMS-936564 / MDX-1338)

Molecule:

CXCR4

Synonyms:

C-X-C chemokine receptor type 4, CXCR4, SDF-1, CD184, BMS-936564, MDX1338

Cat. No.:

DHF39901B pdf (datasheet)

Quantity/Size:

1.0 mg

Price:

$1,520.00 BUY

Concentration:

1.0 mg/ml, lot specific

Description:

Ulocuplumab (BMS-936564, MDX-1338) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. The CXCR4/CXCL12 (SDF-1) axis has been known for many years as a critical regulator of tumor proliferation, cell, as well as migration into and out of the bone marrow. CXCR4 is overexpressed in more than 23 types of human cancers and contributes to tumor growth, angiogenesis, metastasis, and therapeutic resistance. Ulocuplumab was developed for the treatment of hematologic malignancies.

Entrez Symbol:

CXCR4

Uniprot Name:

C-X-C chemokine receptor type 4

Uniprot ID:

P61073

Data PDF:

DHF39901

Purity:

> 95% as determined by SDS-PAGE

Specificity:

Human CXCR4

Host Species:

Human

Isotype:

IgG4 kappa

Formulation:

0.01M PBS, pH 7.4

Purification:

Protein A/G affinity chromatography

Application:

FS

Storage/Stability:

Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.